Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 1.00 |
| ▸ | PPARG | P37231 | 7/20 | 0.61 |
| ▸ | MAOA | P21397 | 2/20 | 0.61 |
| ▸ | CISD1 | Q9NZ45 | 2/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.56 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.56 |
| ▸ | FFAR1 | O14842 | 5/20 | 0.56 |
| ▸ | PPARA | Q07869 | 2/20 | 0.56 |
| ▸ | MAOB | P27338 | 2/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | TP53 | P04637 | 1/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.51 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9570559 | 0.91 | MAPT (0.83) | MAPTPPARGMAOACISD1ALDH1A1 | |
| SCHEMBL8981830 | 0.88 | MAPT (0.79) | MAPTPPARGMAOACISD1ALDH1A1 | |
| SCHEMBL8981836 | 0.88 | MAPT (0.79) | MAPTPPARGMAOACISD1ALDH1A1 | |
| SCHEMBL8544069 | 0.88 | MAPT (0.79) | MAPTPPARGMAOACISD1ALDH1A1 | |
| SCHEMBL290413 | 0.86 | MAPT (0.75) | MAPTPPARGMAOACISD1ALDH1A1 | |
| SCHEMBL4852588 | 0.84 | MAPT (0.73) | MAPTPPARGMAOACISD1ALDH1A1 | |
| Glitazone SCHEMBL623021 | 0.84 | MAPT (0.73) | MAPTPPARGMAOACISD1ALDH1A1 | |
| SCHEMBL5576600 | 0.83 | MAPT (0.71) | MAPTPPARGMAOACISD1ALDH1A1 | |
| SCHEMBL8857164 | 0.83 | MAPT (0.71) | MAPTPPARGMAOACISD1ALDH1A1 | |
| SCHEMBL1411677 | 0.83 | MAPT (0.71) | MAPTPPARGMAOACISD1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3205645-B1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2019-10-23 | — | — | EP | disclosed |
| US-9957251-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-05-01 | — | — | US | disclosed |
| EP-3205645-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2017-08-16 | — | — | EP | disclosed |
| US-20170044132-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-02-16 | — | — | US | disclosed |
| WO-2009123986-A1 | APOPTOSIS SIGNAL-REGULATING KINASE 1 INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-10-08 | — | — | WO | disclosed |
| US-7183276-B2 | Azole compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-02-27 | — | — | US | disclosed |
| US-20050090534-A1 | Azole compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2005-04-28 | — | — | US | disclosed |
| EP-1486490-A1 | AZOLE COMPOUNDS | Takeda Chemical Industries, Ltd. (JP) | 2004-12-15 | — | — | EP | disclosed |
| US-20030158245-A1 | Fused heterocyclic derivatives, their production and use | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2003-08-21 | — | — | US | disclosed |
| US-6552054-B1 | For prophylaxis and therapy of bone diseases and chondropathy | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2003-04-22 | — | — | US | disclosed |
| EP-0587499-B1 | Benzopyran compounds, process for their preparation and their use as cell protectors | ADIR (FR) | 1998-04-29 | — | — | EP | disclosed |
| US-5395834-A | Antiarthritic agents or cardiovascular disorders | ADIR ET COMPAGNIE (FR) | 1995-03-07 | — | — | US | disclosed |
| US-5393775-A | Administering a (2-chromanyl)alkylcarboxylic acid for disorders connected with peroxidation processes | ADIR ET COMPAGNIE (FR) | 1995-02-28 | — | — | US | disclosed |
| US-5330998-A | Anticholesterol agents | PFIZER INC. (US) | 1994-07-19 | — | — | US | disclosed |
| US-5315017-A | Peroxidation and eicosanoid biosynthesis inhibition | ADIR ET COMPAGNIE (FR) | 1994-05-24 | — | — | US | disclosed |
| EP-0389699-B1 | Thiazolidinedione derivatives as hypoglycemic agents | PFIZER (US) | 1994-05-11 | — | — | EP | disclosed |
| EP-0587499-A1 | Benzopyran compounds, process for their preparation and their use as cell protectors | ADIR ET COMPAGNIE (FR) | 1994-03-16 | — | — | EP | disclosed |
| EP-0512899-A1 | Benzopyran compounds, process for their preparation and pharmaceutical compositions containing them | ADIR ET COMPAGNIE (FR) | 1992-11-11 | — | — | EP | disclosed |
| EP-0389699-A1 | Thiazolidinedione derivatives as hypoglycemic agents | PFIZER INC. (US) | 1990-10-03 | — | — | EP | disclosed |
| WO-1989008652-A1 | THIAZOLIDINEDIONE DERIVATIVES AS HYPOGLYCEMIC AGENTS | PFIZER INC. (US) | 1989-09-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050090534-A1 | Azole compounds | AHR, NR0B2, NR2C2 | MAPT 3958/4885PPARG 1249/4885MAOA 1426/4885 |
| US-20030158245-A1 | Fused heterocyclic derivatives, their production and use | TST, STS, AHR | MAPT 4852/4885PPARG 245/4885MAOA 1557/4885 |
| US-20170044132-A1 | HETEROCYCLIC COMPOUND | CDK19, CDK9, CDK8 | MAPT 2330/4885PPARG 3488/4885MAOA 3931/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.